[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 27 of about 27
1. Nanus DM, Garino A, Milowsky MI, Larkin M, Dutcher JP: Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma. Cancer; 2004 Oct 1;101(7):1545-51
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma.
  • BACKGROUND: Immunotherapy is generally ineffective in patients with sarcomatoid renal cell carcinoma (RCC) and in patients with rapidly progressive metastatic or locally recurrent disease, with a median time to progression of approximately 2 months and a median survival of 4-7 months.
  • Gemcitabine-based regimens have modest antitumor activity, whereas doxorubicin is often used to treat sarcomatoid RCC.
  • Based on the antitumor activity of doxorubicin and gemcitabine in collecting duct carcinoma of the kidney, the authors used this combination to treat selected patients with sarcomatoid or rapidly progressing RCC.
  • METHODS: Eighteen patients (11 males and 7 females; median age, 53 years; range, 31-81 years) with RCC (56% sarcomatoid; 44% other) were treated at 2 institutions in a collaborative study that was not institutional review board reviewed.
  • Seven patients received previous treatment with interferon or interleukin-2.
  • Sites of metastases included the lung, soft tissue, bone, liver, and brain with 88% of patients having > or = 3 sites of disease.
  • Treatment consisted of doxorubicin (50 mg/m2) and gemcitabine (1500 or 2000 mg/m2) every 2-3 weeks with granulocyte-colony-stimulating factor support.
  • Therapy was well tolerated with no Grade 4 toxicities.
  • CONCLUSIONS: These data suggested that the combination of doxorubicin and gemcitabine has antitumor activity in patients with sarcomatoid RCC or with rapidly progressing RCC.
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / administration & dosage. Carcinoma, Renal Cell / drug therapy. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Doxorubicin / administration & dosage. Kidney Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2004 American Cancer Society.
  • (PMID = 15378501.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 0 / Recombinant Proteins; 0W860991D6 / Deoxycytidine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 80168379AG / Doxorubicin; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


2. Goto T, Maeshima A, Oyamada Y, Kato R: Solitary pulmonary metastasis from prostate sarcomatoid cancer. World J Surg Oncol; 2010;8:101
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary pulmonary metastasis from prostate sarcomatoid cancer.
  • BACKGROUND: Pulmonary metastasis from prostate cancer is considered to be a late event, and patients can be treated with chemotherapy or hormonal manipulation.
  • Histopathological examination revealed a poorly differentiated adenocarcinoma with a sarcomatoid carcinoma component.
  • During postoperative follow-up, chest computed tomography showed a nodular shadow in the lung, and thoracoscopic wedge resection of the lung was performed.
  • Histopathological examination revealed a histological appearance similar to that of the prostate sarcomatoid carcinoma.
  • This is the first reported case of solitary pulmonary metastasis from prostate sarcomatoid cancer.
  • CONCLUSION: Isolated pulmonary metastasis from prostate sarcomatoid cancer is extremely rare, but surgery could be the treatment of choice.
  • [MeSH-major] Carcinosarcoma / secondary. Lung Neoplasms / secondary. Pneumonectomy / methods. Prostatic Neoplasms / pathology
  • [MeSH-minor] Aged. Diagnosis, Differential. Follow-Up Studies. Humans. Male. Positron-Emission Tomography. Prostatectomy. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1984 Dec 15;54(12):3078-84 [6498785.001]
  • [Cites] Urol Clin North Am. 1991 Feb;18(1):55-63 [1899495.001]
  • [Cites] J Comput Assist Tomogr. 1999 Sep-Oct;23(5):761-3 [10524863.001]
  • [Cites] Cancer. 1995 Jun 1;75(11):2706-9 [7743474.001]
  • [Cites] J Urol. 1999 Dec;162(6):2102 [10569587.001]
  • [Cites] Hum Pathol. 2000 May;31(5):578-83 [10836297.001]
  • [Cites] Mil Med. 2000 Dec;165(12):973-4 [11149072.001]
  • (PMID = 21092117.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2995788
  •  go-up   go-down


3. Shimomura T, Ikemoto I, Yamada H, Hayashi N, Ito H, Oishi Y: Sarcomatoid renal cell carcinoma with a chromophobe component producing beta-human chorionic gonadotropin. Int J Urol; 2005 Sep;12(9):835-7
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sarcomatoid renal cell carcinoma with a chromophobe component producing beta-human chorionic gonadotropin.
  • We report a case of sarcomatoid renal cell carcinoma with a chromophobe component showing significant elevation of beta-human chorionic gonadotropin (beta-HCG) in the peripheral blood.
  • However, 3 months later, masses were discovered in the left renal bed and in the lung in association with elevated serum levels of beta-HCG.
  • The patient was rehospitalized and received combination therapy with interferon-alpha and doxorubicin-based multiple chemotherapy (cyclophosphamide, vincristine, doxorubicin, and dacarbazine).
  • The recurrent mass responded extremely well to treatment, and beta-HCG normalized.
  • However, the patient died 14 months after nephrectomy because of eventual resistance to chemotherapy.
  • Sarcomatoid renal cell carcinoma containing beta-HCG positive cells were pathologically diagnosed with immunohistochemical staining in the left kidney.
  • Sarcomatoid renal cell carcinoma is a variant of renal adenocarcinoma which has a poor prognosis.
  • This patient had an extremely rare sarcomatoid renal cell carcinoma associated with serum levels of beta-HCG which were elevated and strongly correlated with morphologic cancer activity. beta-HCG might be a useful serum marker for detecting and monitoring this renal cell carcinoma.
  • [MeSH-major] Carcinoma, Renal Cell / metabolism. Carcinoma, Renal Cell / pathology. Chorionic Gonadotropin, beta Subunit, Human / biosynthesis. Kidney Neoplasms / metabolism. Kidney Neoplasms / pathology

  • Genetic Alliance. consumer health - Chromophobe Renal Cell Carcinoma.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Int J Urol. 2006 Jan;13(1):99
  • (PMID = 16201981.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin, beta Subunit, Human
  •  go-up   go-down


Advertisement
4. Masue T, Taniguchi M, Takeuchi T, Sakai S: [A case report of sarcomatoid carcinoma of the bladder with metastasis to small intestine]. Nihon Hinyokika Gakkai Zasshi; 2005 Sep;96(6):640-3
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case report of sarcomatoid carcinoma of the bladder with metastasis to small intestine].
  • Pathological diagnosis was TCC G3 with sarcomatoid carcinoma, pT2pR0pL1 pVlpN0.
  • Adjuvant chemotherapy was not performed because of his transient poor conditions.
  • Lung metastasis was observed 6 months postoperatively.
  • Despite of M-VAC therapy and radiation therapy, additional metastases to brain and liver were observed.
  • One month later, partial ileectomy specimen for occlusive ileum revealed the same histologic findings, TCC G3 with sarcomatoid carcinoma.
  • To our knowledge, this is the first case of sarcomatoid carcinoma of the bladder with metastasis to small intestine, although 6 cases of transitional cell carcinoma of the bladder with metastasis to small intestine has been reported in Japan.
  • [MeSH-major] Carcinoma, Transitional Cell / secondary. Carcinosarcoma / secondary. Ileal Neoplasms / secondary. Urinary Bladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16218407.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 11
  •  go-up   go-down


5. García Mediero JM, Alonso Dorrego JM, Nuñez Mora C, Pastor Arquero T, De Fata FR, Cisneros Ledo J, Perez Mies B, Picazo García ML, de la Peña Barthel YJ: [Early-onset sarcomatoid renal carcinoma. Report of a new case and comparison of the same case with another appearing at a mature age]. Arch Esp Urol; 2002 Sep;55(7):843-7
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Early-onset sarcomatoid renal carcinoma. Report of a new case and comparison of the same case with another appearing at a mature age].
  • [Transliterated title] Carcinoma renal sarcomatoide de temprana aparición. Aportación de un nuevo caso y comparación del mismo con otro de aparición en edad madura.
  • We also review etiological, diagnostic and therapeutic features.
  • RESULTS: Despite aggressive surgery and adjuvant chemotherapy it has a very poor prognosis, with disease progression within 6 months in both cases.
  • CONCLUSIONS: Sarcomatoid renal cell carcinoma is an infrequent entity, extremely aggressive and requires radical surgery at the time of diagnosis due to its advanced stage, although results are poor.
  • [MeSH-minor] Adult. Age of Onset. Aged. Antineoplastic Agents, Phytogenic / therapeutic use. Chemotherapy, Adjuvant. Disease Progression. Fatal Outcome. Female. Hepatectomy / methods. Humans. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Lymph Node Excision. Nephrectomy. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12380314.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; Comparative Study; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 5J49Q6B70F / Vincristine
  •  go-up   go-down


6. Park JY, Kim HS, Zo JI, Lee S, Choi SW: Initial presentation of lung sarcomatoid carcinoma as a metastatic lesion in the mandibular gingiva. J Periodontol; 2006 Apr;77(4):734-7
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Initial presentation of lung sarcomatoid carcinoma as a metastatic lesion in the mandibular gingiva.
  • BACKGROUND: Sarcomatoid carcinoma of the lung is a very rare type of tumor characterized by distant metastasis.
  • METHODS: The clinical features of gingival metastasis as an initial presentation of lung sarcomatoid carcinoma are discussed.
  • RESULTS: The histologic and immunohistochemical diagnosis was metastatic carcinoma.
  • To locate the primary tumor, we analyzed the lung lesion by chest computerized tomography (CT) scans and biopsy.
  • The patient was ultimately diagnosed with sarcomatoid carcinoma of the lung with gingival metastasis.
  • Palliative chemotherapy for lung cancer was administered.
  • The gingival lesion disappeared after chemotherapy.
  • [MeSH-major] Carcinoma / secondary. Gingival Neoplasms / secondary. Lung Neoplasms / pathology. Sarcoma / secondary

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16584358.001).
  • [ISSN] 0022-3492
  • [Journal-full-title] Journal of periodontology
  • [ISO-abbreviation] J. Periodontol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Inomata M, Kawagishi Y, Yamada T, Miwa T, Hayashi R, Kashii T, Matsui S, Fukuoka J, Tobe K: [Two cases of pulmonary sarcomatoid carcinoma mimicking malignant mesothelioma]. Nihon Kokyuki Gakkai Zasshi; 2010 Jan;48(1):33-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of pulmonary sarcomatoid carcinoma mimicking malignant mesothelioma].
  • We report 2 cases of pulmonary sarcomatoid carcinoma mimicking malignant mesothelioma.
  • We diagnosed pulmonary sarcomatoid carcinoma and started chemotherapy with carboplatin and paclitaxel, but it was ineffective.
  • We diagnosed pulmonary sarcomatoid carcinoma and started chemotherapy with carboplatin and paclitaxel.
  • The pulmonary sarcomatoid carcinoma was reported to have spred to the pleural and chest wall.
  • The present two cases showed prominent chest wall and pleural tumors with obscure primary lung tumors.
  • Therefore, we needed to differentiate sarcomatoid carcinoma from malignant pleural mesothelioma.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / diagnosis. Lung Neoplasms / diagnosis. Mesothelioma / diagnosis

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20163019.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 19
  •  go-up   go-down


8. Shoji F, Maruyama R, Okamoto T, Ikeda J, Nakamura T, Wataya H, Ichinose Y: Long-term survival after an aggressive surgical resection and chemotherapy for stage IV pulmonary giant cell carcinoma. World J Surg Oncol; 2005 Jun 2;3:32

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival after an aggressive surgical resection and chemotherapy for stage IV pulmonary giant cell carcinoma.
  • BACKGROUND: Pulmonary giant cell carcinoma is one of the rare histological subtypes with pleomorphic, sarcomatoid or sarcomatous elements.
  • The prognosis of patients with this tumor tends to be poor, because surgery, irradiation and chemotherapy are not usually effective.
  • CASE PRESENTATION: We herein report a patient with pulmonary giant cell carcinoma with stage IV disease in whom aggressive multi-modality therapy resulted in a long-term survival.
  • Thereafter, two different regimens of chemotherapy and a partial resection for other site of small intestinal metastases and a splenectomy for splenic metastases were performed.
  • CONCLUSION: This is a first report of a rare case with stage IV pulmonary giant cell carcinoma who has survived long-term after undergoing aggressive surgical treatment and chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lung Cancer. 2001 Oct;34(1):91-7 [11557118.001]
  • [Cites] Eur Respir J. 2001 Dec;18(6):1059-68 [11829087.001]
  • [Cites] Clin Chest Med. 2002 Mar;23(1):65-81, viii [11901921.001]
  • [Cites] Cancer. 1994 Jun 15;73(12):2936-45 [8199991.001]
  • [Cites] J Clin Oncol. 2004 Jan 15;22(2):330-53 [14691125.001]
  • [Cites] Cancer. 1995 Jan 1;75(1 Suppl):191-202 [8000996.001]
  • [Cites] J Thorac Cardiovasc Surg. 2002 Apr;123(4):695-9 [11986597.001]
  • (PMID = 15929799.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1173139
  •  go-up   go-down


9. Armah HB, Parwani AV: Sarcomatoid urothelial carcinoma with choriocarcinomatous features: first report of an unusual case. Urology; 2007 Oct;70(4):812.e11-4
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sarcomatoid urothelial carcinoma with choriocarcinomatous features: first report of an unusual case.
  • The tumor was composed of conventional urothelial carcinoma with sarcomatoid and choriocarcinomatous features, both positive for epithelial markers (pancytokeratin, AE1/AE3, and CAM 5.2).
  • Treatments included surgery, chemotherapy, and radiation therapy.
  • The clinical course was aggressive, with liver, lung, and distant lymph node metastases and a postdiagnosis survival of 6 months.
  • This is the first report, to our knowledge, indicating both sarcomatoid and choriocarcinomatous features in a conventional urothelial carcinoma of the bladder.
  • [MeSH-major] Carcinoma, Transitional Cell / pathology. Choriocarcinoma / pathology. Sarcoma / pathology. Urinary Bladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17991575.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Yasunaga M, Ohishi Y, Nishimura I, Tamiya S, Iwasa A, Takagi E, Inoue T, Yahata H, Kobayashi H, Wake N, Tsuneyoshi M: Ovarian undifferentiated carcinoma resembling giant cell carcinoma of the lung. Pathol Int; 2008 Apr;58(4):244-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian undifferentiated carcinoma resembling giant cell carcinoma of the lung.
  • Giant cell carcinoma (GCC) is a highly aggressive variant of sarcomatoid carcinoma of the lung.
  • To date, however, there have been no reported cases of ovarian carcinoma mainly composed of GCC.
  • Herein is reported the case of a 54-year-old Japanese woman with an undifferentiated ovarian carcinoma producing granulocyte colony-stimulating factor (G-CSF) and an inflammatory cytokine.
  • Adjuvant chemotherapy was administered but induced severe heart failure and severe neutropenia, probably due to the presence of hypercytokinemia and excess G-CSF.
  • Upon the appearance of these fatal side-effects the chemotherapy was immediately discontinued and replaced with radiotherapy.
  • The recognition of this type of ovarian tumor is important for clinical management, because adjuvant chemotherapy is the standard treatment for clinical management of epithelial ovarian cancer.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Giant Cell / diagnosis. Lung Neoplasms / diagnosis. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols. Biomarkers, Tumor / metabolism. Chemotherapy, Adjuvant / adverse effects. Diagnosis, Differential. Disease-Free Survival. Fallopian Tubes / surgery. Female. Granulocyte Colony-Stimulating Factor / metabolism. Humans. Middle Aged. Mucin-1 / metabolism. Ovariectomy. Radiotherapy, Adjuvant. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18324918.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mucin-1; 143011-72-7 / Granulocyte Colony-Stimulating Factor
  •  go-up   go-down


11. Morawietz L, Kuhnen C, Katenkamp D, Le Coutre P, Ladhoff A, Petersen I: Unusual sarcomatoid neoplasm of the lung suggesting a myofibrosarcoma. Virchows Arch; 2005 Dec;447(6):990-5
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual sarcomatoid neoplasm of the lung suggesting a myofibrosarcoma.
  • Clinically suggestive for a lung carcinoma, the tumor showed typical features of a myofibrosarcoma.
  • Shortly after resection of the primary tumor, the patient showed multiple distant metastases in the contralateral lung, the mediastinal lymph nodes, the left adrenal gland, and the pectoral and deltoid muscle, which responded well to chemotherapy.
  • The case report will discuss the evidence for the final diagnosis of a primary pulmonary myofibrosarcoma and the differential diagnosis of sarcomatoid tumors of the lung.
  • [MeSH-major] Fibrosarcoma / pathology. Lung Neoplasms / pathology. Myosarcoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1973 Jan;31(1):191-208 [4683037.001]
  • [Cites] Hum Pathol. 1996 Oct;27(10):1095-8 [8892598.001]
  • [Cites] Pathologe. 2003 Mar;24(2):128-35 [12673503.001]
  • [Cites] Am J Surg Pathol. 2001 Feb;25(2):219-28 [11176071.001]
  • [Cites] J Dermatol. 2001 Jul;28(7):383-7 [11510507.001]
  • [Cites] Am J Clin Pathol. 1994 Sep;102(3):331-40 [8085557.001]
  • [Cites] Am J Surg Pathol. 2001 Dec;25(12 ):1501-7 [11717539.001]
  • [Cites] Ultrastruct Pathol. 1993 Nov-Dec;17(6):611-22 [8122327.001]
  • [Cites] Cancer Genet Cytogenet. 2002 Aug;137(1):33-42 [12377411.001]
  • [Cites] Am J Surg Pathol. 1998 Feb;22(2):141-7 [9500214.001]
  • [Cites] Verh Dtsch Ges Pathol. 1998;82:75-82 [10095420.001]
  • [Cites] Cancer. 2002 Jan 15;94(2):459-69 [11905413.001]
  • [Cites] Am J Surg Pathol. 1998 Oct;22(10):1228-38 [9777985.001]
  • [Cites] Hum Pathol. 2004 Jun;35(6):711-21 [15188137.001]
  • [Cites] Am J Surg Pathol. 2002 Mar;26(3):393-4; author reply 394-6 [11981942.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):350-62 [8996162.001]
  • [Cites] Br J Cancer. 1997;75(1):79-86 [9000602.001]
  • [Cites] Cancer. 2004 Feb 25;102(1):41-54 [14968417.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13784-9 [11707590.001]
  • [Cites] Am J Surg Pathol. 1997 Apr;21(4):489-96 [9130998.001]
  • [Cites] Am J Surg Pathol. 1979 Dec;3(6):535-42 [534390.001]
  • [Cites] Virchows Arch. 2004 Sep;445(3):215-23 [15173943.001]
  • (PMID = 16158184.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


12. Fujiwara Y, Kiura K, Tabata M, Takigawa N, Hotta K, Umemura S, Omori M, Gemba K, Ueoka H, Tanimoto M: Remarkable shrinkage of sarcomatoid renal cell carcinoma with single-agent gemcitabine. Anticancer Drugs; 2008 Apr;19(4):431-3
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Remarkable shrinkage of sarcomatoid renal cell carcinoma with single-agent gemcitabine.
  • Computed tomography showed a tumor in the left kidney and metastases in the left gluteus maximus muscle and lung.
  • The pathological diagnosis of a biopsy specimen obtained from a metastatic lesion in the left gluteus maximus muscle was sarcomatoid renal cell carcinoma.
  • This seriously ill patient suffering from advanced sarcomatoid renal cell carcinoma was treated with single-agent gemcitabine, resulting in symptom relief and a dramatic improvement in his status; all of the tumors had regressed significantly by the 11th dose of gemcitabine.
  • These findings indicate that single-agent gemcitabine is one of the few chemotherapeutic agents effective for palliation in patients with sarcomatoid renal cell carcinoma, even those with poor performance status.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Carcinoma, Renal Cell / drug therapy. Deoxycytidine / analogs & derivatives. Kidney Neoplasms / drug therapy
  • [MeSH-minor] Buttocks / pathology. Humans. Lung Neoplasms / radiography. Lung Neoplasms / secondary. Male. Middle Aged. Muscle Neoplasms / secondary. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18454054.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


13. Froehner M, Gaertner HJ, Manseck A, Wirth MP: Durable complete remission of metastatic sarcomatoid carcinoma of the bladder with cisplatin and gemcitabine in an 80-year-old man. Urology; 2001 Nov;58(5):799
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Durable complete remission of metastatic sarcomatoid carcinoma of the bladder with cisplatin and gemcitabine in an 80-year-old man.
  • A patient with a durable, complete, local and pulmonary remission of a metastatic sarcomatoid carcinoma of the bladder treated with gemcitabine and cisplatin is presented.
  • Sarcomatoid carcinoma arising in the bladder is a rare and notoriously aggressive variant of urothelial carcinoma for which an effective systemic treatment has not been reported up to now.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinosarcoma / drug therapy. Deoxycytidine / analogs & derivatives. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Cisplatin / administration & dosage. Humans. Lung Neoplasms / secondary. Male. Remission Induction

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11711370.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


14. Rawat A, Amato RJ: Phase II Study of thalidomide, Interleukin-2 (IL-2), and granulocyte macrophage-colony stimulating factor (GM-CSF) in patients with metastatic renal cell carcinoma (RCC). J Clin Oncol; 2004 Jul 15;22(14_suppl):4702

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II Study of thalidomide, Interleukin-2 (IL-2), and granulocyte macrophage-colony stimulating factor (GM-CSF) in patients with metastatic renal cell carcinoma (RCC).
  • : 4702 Background: Thalidomide's anti-RCC activity, the potential that its immunomodulatory and anti-angiogenic effects may augment the antitumor activity of IL-2, and the promising early efficacy and safety findings observed with the combination of low dose sc IL-2 plus thalidomide therapy in the treatment of patients with metastatic RCC (ASCO, 2003) form the foundation for the current study.
  • METHODS: Eligibility includes histologic diagnosis of confirmed RCC excluding papillary, sarcomatoid, or collecting duct tumors, measurable disease, normal organ/marrow function, life expectancy >3 months, Zubrod performance status ≤ 2, no prior chemotherapy or immunotherapy, and no active CNS disease.
  • Response was assessed every 2 therapy cycles.
  • One patient is inevaluable for response secondary to CNS toxicity and early removal from therapy.
  • Sites included: lung (N=10), nodal (N=3), liver (N=2), bone( N=1).
  • CONCLUSIONS: Enrollment is ongoing, further data regarding response rate, time to progression, and toxicity will be presented.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016749.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Antonelli A, Simeone C, Ferrari V, Tardanico R, Cunico SC: Durable and complete remission of a metastatic bladder sarcomatoid carcinoma with chemotherapic and surgical treatments. Arch Ital Urol Androl; 2006 Jun;78(2):67-70
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Durable and complete remission of a metastatic bladder sarcomatoid carcinoma with chemotherapic and surgical treatments.
  • The sarcomatoid carcinoma of the urinary bladder is a rare variant of transitional carcinomas with an extremely aggressive clinical course and dismal prognosis regardless therapies.
  • The diagnosis of a bladder sarcomatoid carcinoma involving perivesical tissues with limphnodal, hepatic and lung metastasis was done in a 34-years old male.
  • The disease underwent complete remission after neoadjuvant chemotherapy with adriblastine and ifosfamide, radical surgery and adjuvant chemotherapy with the same drugs, as confirmed by CT, vesical biopsies during chemotherapy and by the findings detected on the surgical specimen.
  • The sarcomatoid bladder carcinoma is a rare variant of transitional carcinoma (0.31%), usually diagnosed in the late decades of life, with a survival time of a few months for metastatic patients regardless of any adopted therapies.
  • Due to the rarity of the disease and the consequent unfeasibility of randomized studies, in our opinion these results, even if obtained in a single case, suggest a viable therapeutic option.

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16929607.001).
  • [ISSN] 1124-3562
  • [Journal-full-title] Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica
  • [ISO-abbreviation] Arch Ital Urol Androl
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents, Alkylating; 80168379AG / Doxorubicin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


16. Ito K, Oizumi S, Fukumoto S, Harada M, Ishida T, Fujita Y, Harada T, Kojima T, Yokouchi H, Nishimura M, Hokkaido Lung Cancer Clinical Study Group: Clinical characteristics of pleomorphic carcinoma of the lung. Lung Cancer; 2010 May;68(2):204-10
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical characteristics of pleomorphic carcinoma of the lung.
  • BACKGROUND: Pleomorphic carcinoma of the lung is a malignant epithelial tumor that contains carcinomatous and sarcomatoid components.
  • METHOD: We retrospectively investigated 22 cases of pleomorphic carcinoma of the lung.
  • Chest computed tomography (CT) findings revealed that the tumors were quite large (mean diameter 45.3+/-21.9mm; range 14-110mm), and 21 tumors were peripherally located.
  • Positron emission tomography with 18-fluorodeoxy-glucose (FDG-PET) was performed in 12 patients, and the Standardized Uptake Value (SUV) tended to be high (9.44+/-4.98).
  • Patients who had received surgical treatment with proper follow-up care survived longer than those who did not undergo surgery.
  • Responses to chemotherapy were generally poor, although 1 patient exhibited partial response to gefitinib.
  • CONCLUSIONS: Pulmonary pleomorphic carcinoma has strong malignant potential with frequent distant metastases, as has already been reported.
  • However, this study demonstrated that surgical treatment and appropriate follow-up therapy might result in better prognoses.
  • [MeSH-major] Lung Neoplasms / diagnosis. Lung Neoplasms / pathology. Lung Neoplasms / physiopathology
  • [MeSH-minor] Aged. Aged, 80 and over. Disease Progression. Drug Resistance, Neoplasm. Female. Hemoptysis. Humans. Male. Middle Aged. Neoplasm Metastasis. Positron-Emission Tomography. Retrospective Studies. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19577320.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


17. Ushiki A, Koizumi T, Kobayashi N, Kanda S, Yasuo M, Yamamoto H, Kubo K, Aoyagi D, Nakayama J: Genetic heterogeneity of EGFR mutation in pleomorphic carcinoma of the lung: response to gefitinib and clinical outcome. Jpn J Clin Oncol; 2009 Apr;39(4):267-70
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic heterogeneity of EGFR mutation in pleomorphic carcinoma of the lung: response to gefitinib and clinical outcome.
  • Somatic epidermal growth factor receptor (EGFR) mutations in exons 19 and 21 have been found in non-small cell lung cancer (NSCLC) and are associated with the therapeutic response to gefitinib in patients with advanced NSCLC.
  • We report a case of pleomorphic carcinoma of the lung with different EGFR mutations.
  • Prior to gefitinib treatment, an exon 19 deletion of EGFR mutation was positive in the specimens obtained from pleural effusion and left cervical lymph node, histologically proven to be adenocarcinoma.
  • However, the response to gefitinib was poor and the patient died of progressive disease 4 months after the initiation of gefitinib therapy.
  • Postmortem examination revealed the major histological component to be of the sarcomatoid or pleomorphic type with scant mixed adenocarcinoma, resulting in a histological diagnosis of pleomorphic carcinoma of the lung.
  • Although the adenocarcinomatous tissue was still positive for exon 19 deletion of EGFR mutation alone, sarcomatous components had both the exons 19 deletion and 20 T790M mutation concomitantly, thought to be a gefitinib resistance mutation.
  • Pulmonary pleomorphic carcinoma is a rare NSCLC composed of biphasic and heterogeneous malignant cell populations.
  • The present case suggested that expression of different EGFR mutations is related to the biphasic histological appearance in pulmonary pleomorphic carcinoma.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / genetics. Genes, erbB-1 / genetics. Lung Neoplasms / drug therapy. Lung Neoplasms / genetics. Neoplasms, Multiple Primary / drug therapy. Neoplasms, Multiple Primary / genetics. Sequence Deletion
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / genetics. Adenocarcinoma / secondary. Antineoplastic Agents / therapeutic use. Fatal Outcome. Humans. Lymphatic Metastasis. Male. Middle Aged. Quinazolines / therapeutic use. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19155283.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  •  go-up   go-down


18. Carvalho L: Reclassifying bronchial-pulmonary carcinoma: differentiating histological type in biopsies by immunohistochemistry. Rev Port Pneumol; 2009 Nov-Dec;15(6):1101-19
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reclassifying bronchial-pulmonary carcinoma: differentiating histological type in biopsies by immunohistochemistry.
  • The current state of molecular knowledge on lung cancer demands a histological classification which goes beyond small-cell and non-small-cell carcinoma to provide support for tailored therapy in aiding in understanding of the drugs currently available.
  • As diagnosis and follow-up in the vast majority of lung cancer cases is based on biopsies and cytology samples, Immunohistochemical Bronchial Pulmonary Carcinoma Classification (IBPCC) is necessary to reveal the raft of characteristics available.
  • The immunohistochemical panel clarifies the main morphology and cytology characteristics to maintain the leading histological types as squamous cell carcinoma (high weight molecular cytokeratins/HWMC), adenosquamous carcinoma (CK7, TTF1, HWMA), neuroendocrine carcinoma (Chrg, Syn, CD56, TTF1, Ki67), adenocarcinoma (CK7, CK20, TTF1) and bring the polymorphic and pleomorphic carcinomas under a single banner of pleomorphic carcinoma (Ck7, TTF1, HWMC, VMT, Desmin, Actin) which shelters large cell carcinomas and sarcomatoid carcinomas.
  • Lung cancer chemotherapy will still be based on platinum and gemcitabine for the near future and the IBPCC is a simple and efficient tool for streamlining the registration of lung cancer histological characteristics in biopsies and other reduced samples to support clinical evidence and trials.
  • [MeSH-major] Adenocarcinoma / classification. Adenocarcinoma / pathology. Bronchial Neoplasms / classification. Bronchial Neoplasms / pathology. Lung Neoplasms / classification. Lung Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19859629.001).
  • [ISSN] 2172-6825
  • [Journal-full-title] Revista portuguesa de pneumologia
  • [ISO-abbreviation] Rev Port Pneumol
  • [Language] eng; por
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] Portugal
  • [Number-of-references] 80
  •  go-up   go-down


19. Raveglia F, Mezzetti M, Panigalli T, Furia S, Giuliani L, Conforti S, Meda S: Personal experience in surgical management of pulmonary pleomorphic carcinoma. Ann Thorac Surg; 2004 Nov;78(5):1742-7
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for pleomorphic carcinoma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Personal experience in surgical management of pulmonary pleomorphic carcinoma.
  • BACKGROUND: Pleomorphic carcinoma is a rare epithelial malignant tumor.
  • Pulmonary pleomorphic carcinoma was introduced by the 1999 World Health Organization classification as a new peculiar type of lung carcinoma showing concurrent malignant epithelial and sarcomatoid spindle cell elements.
  • My colleagues and I report a series of patients surgically treated for pulmonary pleomorphic carcinoma to describe our experience with this malignant neoplasm.
  • METHODS: Twenty cases of pleomorphic pulmonary carcinoma were collected and studied clinicopathologically.
  • RESULTS: We postoperatively diagnosed 20 cases of pleomorphic carcinoma: 14 cases were exclusively spindle and giant-cell carcinomas, 2 cases were spindle and giant-cell carcinoma combined with adenocarcinoma, 2 were combined with squamous cell carcinoma, and 2 were combined with large cell carcinoma.
  • CONCLUSIONS: The prognosis of patients with pleomorphic carcinoma was poor, despite surgery and adjuvant chemotherapy, because of early relapse of disease.
  • In case of preoperatively proven pulmonary pleomorphic carcinoma, surgery should be recommended to N0 patients.
  • [MeSH-major] Carcinoma / surgery. Lung Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adult. Aged. Carcinoma, Giant Cell / mortality. Carcinoma, Giant Cell / pathology. Carcinoma, Giant Cell / surgery. Cell Differentiation. Disease-Free Survival. Female. Follow-Up Studies. Humans. Life Tables. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15511465.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 20
  •  go-up   go-down


20. Huang C, Wang LC, Xiao JY, Ye ZX, Liu ZJ, Xu WJ, Cheng X, Wang J, Li K: [Analysis of cavitation of advanced NSCLC treated by rh-endostatin combined with NP chemotherapy]. Zhonghua Zhong Liu Za Zhi; 2008 Sep;30(9):712-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of cavitation of advanced NSCLC treated by rh-endostatin combined with NP chemotherapy].
  • OBJECTIVE: To study the significance of intra-tumoral cavitation in the patients with advanced NSCLC treated by rh-endostatin plus NP chemotherapy.
  • METHODS: Fifty-seven patients with advanced NSCLC were randomly assigned to receive chemotherapy with rh-endostatin plus NP or NP alone.
  • Chest computed tomography was performed to evaluate the efficacy after 2 cycles of chemotherapy.
  • Of the 5 patients, there were 2 males and 3 females, with pathological types of 3 adenocarcinomas, 1 adenosquamous cell carcinoma and 1 sarcomatoid carcinoma.
  • The blood-supply of the tumors showed by perfusion CT images was inhibited in 3 cases after treatment.
  • The average number of aCECs decreased from 323.2/10(5) to 33.0/10(5) after treatment.
  • CONCLUSION: Intratumoral cavitation is a peculiar imaging characteristics after anti-angiogenic therapy, which may be caused by inhibition of blood-supply to the tumor.
  • CT perfusion imaging and measurement of activated circulating endothelial cells may be helpful to predict the efficacy of anti-angiogenic therapy combined with chemotherapy.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Endostatins / therapeutic use. Lung Neoplasms / drug therapy
  • [MeSH-minor] Cisplatin / administration & dosage. Female. Humans. Male. Middle Aged. Neoplasm Staging. Recombinant Proteins / therapeutic use. Tomography, X-Ray Computed. Vinblastine / administration & dosage. Vinblastine / analogs & derivatives

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19173919.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Endostatins; 0 / Recombinant Proteins; 5V9KLZ54CY / Vinblastine; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine
  •  go-up   go-down


21. Yangui I, Smaoui M, Khabir A, Ayoub A, Boudawara T: [A rare primary pulmonary tumor: pleomorphic carcinoma]. Presse Med; 2007 Feb;36(2 Pt 1):243-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A rare primary pulmonary tumor: pleomorphic carcinoma].
  • INTRODUCTION: Pleomorphic carcinoma is a rare malignancy in the family of non-small cell lung cancers.
  • Computed tomography showed a peripheral tumor of the right upper lobe, and the radiography showed signs of malignancy.
  • The patient underwent 2 cycles of induction chemotherapy that combined gemcitabine and cisplatin.
  • DISCUSSION: Pleomorphic carcinoma is identified by purely histologic criteria: the concomitant presence of malignant epithelial and homologous sarcomatoid spindle-cell components.
  • Like the other non-small cell lung cancers, treatment is primarily surgical, and the invasive character of this tumor makes it very difficult.
  • Pleomorphic carcinoma has a poorer prognosis than conventional non-small cell lung cancers despite surgery, irradiation and chemotherapy, because relapse occurs early.
  • [MeSH-major] Carcinoma / pathology. Lung Neoplasms / pathology
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Radiography, Thoracic. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17259034.001).
  • [ISSN] 0755-4982
  • [Journal-full-title] Presse medicale (Paris, France : 1983)
  • [ISO-abbreviation] Presse Med
  • [Language] fre
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  •  go-up   go-down


22. Procopio G, Verzoni E, Gevorgyan A, Mancin M, Pusceddu S, Catena L, Platania M, Guadalupi V, Martinetti A, Bajetta E: Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma. Oncology; 2007;73(3-4):204-9
Hazardous Substances Data Bank. NICOTINAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma.
  • BACKGROUND: The aim of our study was to evaluate the efficacy and safety in unresectable or advanced renal carcinoma treated with sorafenib, in a situation closely similar to the everyday medical practice.
  • They were either previously untreated or relapsed after one or more previous treatments with systemic therapy.
  • Most of them had clear cell renal carcinoma (RCC), but other histological types such as papillary, chromophobe, Bellini ducts, sarcomatoid and mixed forms were also represented.
  • CONCLUSIONS: The results confirm previous ones reported in the literature concerning the efficacy and the safety of sorafenib as second-line treatment in patients with RCC.
  • In addition, they disclose the hypothesis that sorafenib could be effective also in patients who underwent multiple previous treatments and in those with histology different from clear cells.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Benzenesulfonates / therapeutic use. Carcinoma, Renal Cell / drug therapy. Kidney Neoplasms / drug therapy. Pyridines / therapeutic use
  • [MeSH-minor] Administration, Oral. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Carcinoma, Papillary / drug therapy. Carcinoma, Papillary / secondary. Disease Progression. Drug Resistance, Neoplasm. Female. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Male. Middle Aged. Neoplasm Staging. Niacinamide / analogs & derivatives. Phenylurea Compounds. Prognosis. Remission Induction. Salvage Therapy. Survival Rate

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 S. Karger AG, Basel
  • (PMID = 18418013.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  •  go-up   go-down


23. Lou E, Kellman RM, Hutchison R, Shillitoe EJ: Clinical and pathological features of the murine AT-84 orthotopic model of oral cancer. Oral Dis; 2003 Nov;9(6):305-12
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This was done because testing of new treatments for oral cancer requires the use of a realistic animal model.
  • The therapeutic effects of surgery, 5-fluorouracil and cisplatin were measured on the orthotopic tumors.
  • RESULTS: Tumors had the histological appearance of a sarcomatoid carcinoma, invading locally and causing weight loss and death.
  • Tumors could be treated with some success by surgery or chemotherapy, but generally recurred.
  • CONCLUSIONS: The similarities to human oral cancer suggest that the model will be very useful in the evaluation of experimental therapies for oral cancer.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Disease Models, Animal. Mouth Neoplasms / pathology
  • [MeSH-minor] Animals. Antimetabolites, Antineoplastic / therapeutic use. Cell Line, Tumor. Fluorouracil / therapeutic use. Humans. Lung Neoplasms / secondary. Mice. Mice, Inbred C3H. Neoplasm Invasiveness. Neoplasm Recurrence, Local / pathology. Neoplasm Transplantation. Skin Neoplasms / drug therapy. Skin Neoplasms / pathology. Skin Neoplasms / surgery

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14629332.001).
  • [ISSN] 1354-523X
  • [Journal-full-title] Oral diseases
  • [ISO-abbreviation] Oral Dis
  • [Language] eng
  • [Grant] United States / NIDCR NIH HHS / DE / R01 DE13214
  • [Publication-type] Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


24. Trepp R, Padberg BC, Varga Z, Cathomas R, Inauen R, Reinhart WH: Extensive extranodal metastases of basal-like breast cancer with predominant myoepithelial spindle cell differentiation. Pathol Res Pract; 2010 May 15;206(5):334-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A differentiation towards myoepithelial cells has been demonstrated in several types of lesions in the breast.
  • These include multifocal myoepitheliomatosis, the rare mixed tumor or pleomorphic adenoma, adenoid cystic carcinoma, adenomyoepithelioma and myoepithelial carcinoma (malignant myoepithelioma).
  • Myoepithelial carcinoma is the only lesion purely composed of myoepithelial cells.
  • The presented case of a breast carcinoma with dominant myoepithelial/spindle cell differentiation in a 58-year-old woman is an excellent example to document the highly aggressive biological behavior of this tumor phenotype.
  • Despite an extensive chemotherapy and radiotherapy, the tumor was rapidly progressive, forming a finally exulcerating local tumor relapse and widespread metastases to the myocardium, lungs, liver, kidneys and skin.
  • Similarities in morphology and biological behavior compared to patients with "triple-negative" (hormone receptor and Her2) monophasic sarcomatoid carcinomas and pure spindle cell sarcomas are discussed.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma / secondary. Kidney Neoplasms / secondary. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Skin Neoplasms / secondary


25. Jänne PA, Taffaro ML, Salgia R, Johnson BE: Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma. Cancer Res; 2002 Sep 15;62(18):5242-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have determined the effects of EGFR inhibition in MPM cell lines in vitro, using four MPM cell lines derived from previously untreated patients with epithelial (H2461 and H2591), sarcomatoid (H2373), and biphasic (MSTO-211H) MPM.
  • All four cell lines expressed EGFR at levels comparable with the non-small cell lung carcinoma (NSCLC) cell line A549, as shown by Western blot analysis.
  • Furthermore, treatment with ZD1839 led to a significant dose-dependent reduction of colony formation (41-89% at 10 microM) when MPM cells were grown in soft agarose.
  • Our findings demonstrate that in vitro, ZD1839 is as effective or more effective against MPM cell lines as it is against the NSCLC cell line A549 and suggest that ZD1839 may be an effective therapeutic option for patients with MPM.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Mesothelioma / drug therapy. Pleural Neoplasms / drug therapy. Quinazolines / pharmacology. Receptor, Epidermal Growth Factor / antagonists & inhibitors
  • [MeSH-minor] Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / metabolism. Carcinoma, Non-Small-Cell Lung / pathology. Cell Cycle / drug effects. Cell Division / drug effects. Epidermal Growth Factor / pharmacology. Humans. Lung Neoplasms / drug therapy. Lung Neoplasms / metabolism. Lung Neoplasms / pathology. Phosphorylation. Signal Transduction / drug effects. Signal Transduction / physiology. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12234991.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; 62229-50-9 / Epidermal Growth Factor; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  •  go-up   go-down


26. Yu L, Li X, Yang W: Pulmonary blastoma metastatic to the ovary. Int J Gynecol Pathol; 2009 Jan;28(1):59-62
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 38-year-old woman was diagnosed as biphasic PB (1 subgroup of sarcomatoid carcinoma) and treated by surgery, radiotherapy, and chemotherapy.
  • [MeSH-major] Lung Neoplasms / pathology. Ovarian Neoplasms / secondary. Pulmonary Blastoma / secondary

  • Genetic Alliance. consumer health - Blastoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Gynecol Pathol. 2010 Jul;29(4):339-40 [20567146.001]
  • (PMID = 19047906.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Boroumand N, Raja V, Jones DV, Haque AK: SYT-SSX2 variant of primary pulmonary synovial sarcoma with focal expression of CD117 (c-Kit) protein and a poor clinical outcome. Arch Pathol Lab Med; 2003 Apr;127(4):e201-4
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Previous reports have suggested that the soft tissue synovial sarcomas with SYT-SSX2 phenotype have a favorable clinical outcome.
  • A 45-year-old woman presented with left chest pain and was found to have a left lower lobe tumor that was originally diagnosed as a sarcomatoid carcinoma.
  • After the patient underwent chemotherapy and brachytherapy, the specimen from a left pneumonectomy showed a large spindle cell tumor, which was reclassified as a synovial sarcoma based on the results of immunophenotyping and molecular genetic studies.
  • Differentiation between sarcoma and carcinosarcoma is crucial for implementing appropriate therapy.
  • Furthermore, if the tumor expresses c-Kit, it may respond to target-based therapy.
  • [MeSH-major] Genetic Variation / genetics. Lung Neoplasms / diagnosis. Lung Neoplasms / genetics. Oncogene Proteins, Fusion / genetics. Proto-Oncogene Proteins c-kit / biosynthesis. Sarcoma, Synovial / diagnosis. Sarcoma, Synovial / genetics

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12683902.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Oncogene Proteins, Fusion; 0 / SYT-SSX fusion protein; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down






Advertisement